GlassScriptPhysician profile
Mac L Machan
NPI 1649505496
$8,481.22
in general payments reported to CMS, 2019-2025
35 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 79% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $635 · 2021: $789 · 2022: $1,363 · 2023: $1,167 · 2024: $1,828 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,092 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,092.40 |
| Education | $129.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,277.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $837.31 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $624.49 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $555.12 | 2020-2025 | Tremfya |
| Pfizer INC. | $477.02 | 2019-2024 | |
| Dermavant Sciences, INC. | $443.08 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $417.96 | 2020-2025 | Ilumya |
| Genzyme Corporation | $389.60 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $273.20 | 2020-2021 | |
| Lilly USA, LLC | $243.55 | 2019-2025 | Taltz, Ebglyss |
| Organogenesis INC. | $197.08 | 2019-2024 | Puraply, Puraply Am |
| Organon LLC | $195.27 | 2025 | Vtama |
| Leo Pharma INC. | $186.56 | 2020-2025 | Adbry |
| Acera Surgical, INC. | $150.98 | 2022 | |
| Merz North America, INC. | $143.55 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $125.21 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Aclaris Therapeutics, INC. | $118.74 | 2019 | |
| Ucb, INC. | $109.89 | 2021-2025 | Bimzelx |
| Incyte Corporation | $95.55 | 2021-2025 | Opzelura |
| Genentech USA, INC. | $92.75 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.31 | 2022-2025 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $62.21 | 2023-2024 | Siliq, Duobrii, Cabtreo |
| Novartis Pharmaceuticals Corporation | $55.43 | 2019-2020 | |
| Misonix INC | $47.97 | 2020-2021 | |
| Kerecis Limited | $42.31 | 2021-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Epi Health, LLC | $42.28 | 2019-2022 | |
| Almirall LLC | $33.99 | 2025 | Seysara |
| Helsinn Therapeutics (U.S.), INC. | $31.26 | 2023 | Valchlor |
| Amgen INC. | $30.10 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $29.87 | 2019 | |
| Botanix Sb INC | $18.78 | 2025 | Sofdra |
| Mimedx Group, INC. | $13.67 | 2024 | |
| Journey Medical Corporation | $13.60 | 2022 | |
| Arcutis Biotherapeutics, INC. | $13.52 | 2025 | Zoryve |
| Strata Skin Sciences, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mac Machan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.